• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The CHARM-Preserved trial: Candesartan in heart failure with preserved ejection fraction [Classics Series]

byAndrew Cheung, MD MBA
May 7, 2014
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. In patients with heart failure and preserved ejection fraction, candesartan does not significantly reduce the rate of cardiovascular death, but does significantly reduce the rate of hospitalization for heart failure as compared with placebo

Original Date of Publication: September 6, 2003

Study Rundown: A large body of evidence exists supporting various interventions to improve outcomes in heart failure with reduced left-ventricular ejection fraction (LVEF). The SOLVD and ATLAS trials demonstrated that treatment with angiotensin-converting-enzyme inhibitor (ACE-I) significantly reduced mortality in heart failure patients with reduced LVEF. The Val-HEFT and CHARM-Alternative trials demonstrated the benefits of angiotensin-receptor blocker (ARB) therapy, while the MERIT-HF and COPERNICUS trials supported the use of beta-blockers. The RALES, EMPHASIS-HF, and EPHESUS trials provide evidence for aldosterone blockade in these patients and the MADIT-II trial found that prophylactic implantable defibrillators also reduced mortality.

The literature exploring the treatment of heart failure with preserved LVEF is much more scarce. At the time of the CHARM-Preserved trial, many guidelines for heart failure management did not specifically address treating patients with preserved ejections fractions. Given that there was some evidence to support the use of ACE-Is in treating heart failure with preserved ejection fraction, the aim of the CHARM-Preserved trial was to explore whether angiotensin blockade using an ARB would have similar benefits.

In summary, there were no significant differences between the two groups in terms of the rate of cardiovascular death and hospitalization for heart failure (adjusted HR 0.86; 95%CI 0.74-1.00, p=0.051). There was a small but significant reduction in hospitalizations for heart failure (adjusted HR 0.84; 95%CI 0.70-1.00, p=0.047), while there were a significantly higher rate of adverse events in the candesartan group (17.8% vs. 13.5%, p=0.001).

RELATED REPORTS

Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms

#VisualAbstract: Dapagliflozin Reduced Death and Worsening Heart Failure in Transcatheter Aor-tic-Valve Implantation

AAV9.LAMP2B gene therapy shows clinical benefit in Danon disease

Click to read the study in The Lancet

In-Depth [randomized, controlled study]: This randomized, controlled trial involved 3,025 patients from 618 centres in 26 countries. Patients were eligible for the study if they were 18 years of age or older, had New York Heart Association (NYHA) functional class II-IV symptoms for at least 4 weeks, had a history of hospital admission for a cardiac reason, and had LVEF>40%.  Eligible patients were randomized to receive either candesartan or placebo. The primary outcome was cardiovascular death or unplanned admission to hospital for the management of worsening heart failure. Secondary outcomes included several combinations of cardiovascular death, admission to hospital for heart failure, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, all-cause mortality, and new development of diabetes.

There was no significant difference between the candesartan and placebo groups in terms of the rate of the primary outcome (adjusted HR 0.86; 95%CI 0.74-1.00, p=0.051). Specifically, there was no significant difference between the two groups in terms of the rate of cardiovascular death (adjusted HR 0.95; 95%CI 0.76-1.18, p=0.635). The rate of hospital admission for heart failure was significantly reduced in the candesartan group as compared with the placebo group (adjusted HR 0.84; 95%CI 0.70-1.00, p=0.047). The rates of study-drug discontinuation due to adverse events or laboratory abnormalities were significantly higher in the candesartan group (17.8% vs. 13.5%, p=0.001), with the commonest causes being rising creatinine (4.8% vs. 2.4%, p=0.0005), hypotension (2.4% vs. 1.1%, p=0.009), and hyperkalemia (1.5% vs. 0.6%, p=0.029), all of which were higher in the candesartan group.

© 2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Candesartanheart failure
Previous Post

Women’s Health Initiative results in high-value economic return

Next Post

Age, bone mineral density may predict fracture after alendronate discontinuation

RelatedReports

Lisinopril and carvedilol reduce cardiotoxicity in breast cancer patients receiving trastuzumab and anthracyclines
Cardiology

Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms

June 19, 2025
#VisualAbstract: Dapagliflozin Reduced Death and Worsening Heart Failure in Transcatheter Aor-tic-Valve Implantation
StudyGraphics

#VisualAbstract: Dapagliflozin Reduced Death and Worsening Heart Failure in Transcatheter Aor-tic-Valve Implantation

April 18, 2025
Cardiology

AAV9.LAMP2B gene therapy shows clinical benefit in Danon disease

March 14, 2025
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Finerenone reduces heart failure events in patients with HFpEF

November 26, 2024
Next Post
Repeat bone mineral density testing may not improve prediction of fracture outcomes

Age, bone mineral density may predict fracture after alendronate discontinuation

Malarial transmission substantially reduced in endemic Africa

Severity of malaria infection may be independent of parasite burden

Wound surgical device found ineffective at infection control: ROSSINI Trial

Genetic variant linked to poor patient survival following lung transplantation

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.